HPV Testing and Pap Test Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 6.21 Billion |
| Market Size (2029) | USD 10.33 Billion |
| CAGR (2024 - 2029) | 10.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
HPV Testing and Pap Test Market Analysis
The HPV Testing And Pap Test Market size is estimated at USD 6.21 billion in 2024, and is expected to reach USD 10.33 billion by 2029, growing at a CAGR of 10.70% during the forecast period (2024-2029).
HPV (human papillomavirus) and Pap tests are essential components of cervical cancer screening. HPV is a common sexually transmitted infection that can lead to the development of cervical cancer. Pap tests, on the other hand, involve the collection of cells from the cervix to detect any abnormal changes that may indicate the presence of precancerous or cancerous cells.
The combination of HPV testing and Pap tests has proven to be highly effective in identifying women at risk of developing cervical cancer. HPV testing can detect the presence of high-risk HPV strains, which are strongly associated with the development of cervical cancer. Pap tests, on the other hand, can identify abnormal changes in cervical cells that may indicate the presence of precancerous or cancerous cells.
However, the effectiveness of cervical cancer screening heavily relies on the demand for these tests. This is where government policies and programs play a crucial role. Governments around the world have recognized the importance of cervical cancer screening and have implemented various policies and programs to increase awareness and access to these tests. For instance, India’s interim Union Budget 2024-2025 became a symbol of optimism on the occasion of International Women’s Day, especially in terms of women’s health. The Indian administration's commendable efforts to promote the immunization of girls (aged 9 to 14) against cervical cancer have proven to be a significant step in protecting women's welfare.
Government policies often include guidelines that recommend the frequency and age at which women should undergo cervical cancer screening. These guidelines are based on scientific evidence and aim to ensure that women receive regular screenings at appropriate intervals. By setting these guidelines, governments help healthcare providers and individuals understand the importance of regular screening and the recommended age to start and stop screening.
In conclusion, HPV and Pap tests are crucial components of cervical cancer screening, and government policies and programs play a significant role in increasing the demand for these tests. By implementing guidelines, awareness campaigns, and financial support, governments contribute to the early detection and prevention of cervical cancer, ultimately saving lives.
HPV Testing and Pap Test Market Trends
The Cervical Cancer Screening Test Segment is Expected to be Dominant During the Forecast Period
- Cervical cancer screening is an essential part of a woman’s routine healthcare check-up. For women aged 30 years and above, an HPV test is recommended for detection. The screening helps identify precancerous lesions caused by HPV so they can be removed to prevent invasive cancers from developing.
- The major factor driving the growth of the segment includes the rising burden of cervical cancer worldwide. The disease is more commonly found in females. According to the World Health Organization, more than 270,000 women die every year due to cervical cancer.
- The American Cancer Society has projected that in the United States, in 2024, there will be approximately 13,820 new cases of invasive cervical cancer diagnosed. Additionally, it is estimated that about 4,360 women will succumb to cervical cancer. Moreover, cervical pre-cancers are detected at a much higher frequency than invasive cervical cancer. Cervical cancer can be prevented with early detection and the treatment of abnormal cell changes that occur in the cervix before cervical cancer develops. Therefore, with the increasing adoption of early diagnosis, the market is expected to grow positively during the forecast period.
- The cervical cancer screening tests segment is found to be dominating the market, owing to the increasing awareness about the benefits associated with the early detection of cancer and the rising government support toward controlling cervical cancer. Hence, all these factors are expected to drive the market’s growth.
North America is Expected to Dominate the Market During the Forecast Period
- The market studied in North America has been found to dominate due to the increased number of cervical cancer cases and the growing number of screening procedures.
- There is one HPV test that has been approved (Cobas test) for use as primary cervical cancer screening for women aged 25 years and older, followed by a Pap test for women with certain results. Many new tests in development can improve the evaluation of HPV-positive women. Thus, due to the increasing demand for Pap, HPV, and other tests for cancer screening, the market is expected to grow.
- The American Cancer Society (ACS) estimated that 4,310 deaths from this disease occurred in the United States in 2023. Similar to the incidence rates, the death rate in the United States has declined by around 50% since the mid-1970s because the increase in screening resulted in earlier detection of cervical cancer. However, the death rate is 65% higher in Black women than in White women, even though both groups self-report similar screening efforts. These incidences are expected to propel market growth during the forecast period.
- The favorable government policies in North America are expected to drive the overall market during the forecast period. In the United States, the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for breast and cervical cancer screening has helped in driving the overall market’s growth.
- In addition to guidelines, governments also implement programs to increase the demand for cervical cancer screening. These programs often involve public awareness campaigns that educate women about the importance of screening and the availability of HPV and Pap tests. They may also provide financial support or subsidies to make these tests more affordable and accessible to women, particularly those from low-income backgrounds or underserved communities.
- By implementing such policies and programs, governments contribute significantly to increasing the demand for cervical cancer screening. They help raise awareness about the importance of early detection and prevention, ensuring that more women undergo regular screenings. This, in turn, leads to the early identification and treatment of precancerous or cancerous cells, reducing the incidence and mortality rates associated with cervical cancer.
HPV Testing and Pap Test Industry Overview
The HPV testing and Pap test market is moderately fragmented and consists of several major players. These key players are found focusing on inorganic and organic strategies such as product approvals and licenses, agreements, collaborations, partnerships, expansions, and acquisitions to sustain their growth in the HPV testing and Pap test market. Also, receiving approvals from regulatory authorities for new product launches will give companies a competitive advantage. Some of the major players in the HPV and Pap test market include Abbott Laboratories, Qiagen, Becton, Dickinson and Company, F. and Hoffmann-La Roche Ltd.
HPV Testing and Pap Test Market Leaders
-
Arbor Vita Corporation
-
F. Hoffmann-La Roche Ltd
-
Seegene Inc.
-
Becton, Dickinson and Company
-
Qiagen NV
*Disclaimer: Major Players sorted in no particular order
HPV Testing and Pap Test Market News
- November 2023: Abbott's molecular human papillomavirus (HPV) screening solution was approved by the US Food and Drug Administration (FDA), expanding the range of diagnostic assays within the Alinity m family. This approval introduces a valuable cancer screening tool for the identification of high-risk HPV infections.
- February 2023: The FDA approved BD’s HPV assay for use with a hologic test. The BD Onclarity HPV Assay includes reporting on genotypes 31, 51, 52, 33/58, 35/39/68, and 56/59/66.
HPV Testing and PAP Test Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumption and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Cervical Cancer Cases
4.2.2 Increasing Number of Cervical Cancer Screening Programs
4.2.3 Introduction to Advanced Technologies
4.3 Market Restraints
4.3.1 HPV Vaccination
4.3.2 Changes in Regulatory Guidelines for Cervical Cancer Screening
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Test Type
5.1.1 HPV Test
5.1.2 Pap Test
5.1.3 Co-testing
5.2 By Application
5.2.1 Cervical Cancer Screening Tests
5.2.2 Head and Neck Cancer Screening Tests
5.2.3 Other Applications
5.3 By End User
5.3.1 Hospitals/Clinics
5.3.2 Diagnostic Centers
5.3.3 Point-of-care/Self-sampling
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Arbor Vita Corporation
6.1.2 Danaher Corporation (Cepheid)
6.1.3 Seegene Inc.
6.1.4 Becton, Dickinson and Company
6.1.5 TruScreen
6.1.6 Abbott Laboratories
6.1.7 Hologic Inc.
6.1.8 Qiagen NV
6.1.9 F. Hoffmann-La Roche AG
6.1.10 OncoHealth Corporation
6.1.11 Takara Bio Inc.
6.1.12 Promega Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
HPV Testing and Pap Test Industry Segmentation
As per the scope of the report, the human papillomavirus (HPV) test is used to detect the presence of the human papillomavirus, which leads to the development of genital warts, abnormal cervical cells, or cervical cancer. A Pap smear, also called Pap test or smear test, is a procedure doctors use to find cell changes or abnormal cells in the cervix. A Pap smear removes a microscopic sample of cells from the cervix to test for cancer and precancer. Pap tests are the most preferred tests to detect cervical cancer. These tests include microscopic observation of specimens.
The HPV testing and Pap test market is segmented by test type, application, end user, and geography. By test type, the market is segmented into HPV test, Pap test, and co-testing. The market is segmented by application into cervical cancer screening tests, head and neck cancer screening tests, and other applications. By end user, the market is segmented into hospitals/clinics, diagnostic centers, and point-of-care/self-sampling. Geographically, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (USD) for the above segments.
| By Test Type | |
| HPV Test | |
| Pap Test | |
| Co-testing |
| By Application | |
| Cervical Cancer Screening Tests | |
| Head and Neck Cancer Screening Tests | |
| Other Applications |
| By End User | |
| Hospitals/Clinics | |
| Diagnostic Centers | |
| Point-of-care/Self-sampling |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
HPV Testing and PAP Test Market Research FAQs
How big is the HPV Testing And Pap Test Market?
The HPV Testing And Pap Test Market size is expected to reach USD 6.21 billion in 2024 and grow at a CAGR of 10.70% to reach USD 10.33 billion by 2029.
What is the current HPV Testing And Pap Test Market size?
In 2024, the HPV Testing And Pap Test Market size is expected to reach USD 6.21 billion.
Who are the key players in HPV Testing And Pap Test Market?
Arbor Vita Corporation, F. Hoffmann-La Roche Ltd, Seegene Inc., Becton, Dickinson and Company and Qiagen NV are the major companies operating in the HPV Testing And Pap Test Market.
Which is the fastest growing region in HPV Testing And Pap Test Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in HPV Testing And Pap Test Market?
In 2024, the North America accounts for the largest market share in HPV Testing And Pap Test Market.
What years does this HPV Testing And Pap Test Market cover, and what was the market size in 2023?
In 2023, the HPV Testing And Pap Test Market size was estimated at USD 5.55 billion. The report covers the HPV Testing And Pap Test Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the HPV Testing And Pap Test Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
HPV Testing and PAP Test Industry Report
Statistics for the 2024 HPV Testing and PAP Test market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. HPV Testing and PAP Test analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
